UKONIQ to Treat Marginal Zone Lymphoma and Follicular Lymphoma Clinical Trials Arena - 25 Feb 2021 UKONIQ to Treat Marginal Zone Lymphoma and Follicular Lymphoma ... More
Umbralisib offers hope for patients with relapsed/refractory marginal zone lymphoma | Latest news for Doctors, Nurses ... MIMS - 28 Apr 2019 Umbralisib offers hope for patients with relapsed/refractory marginal zone lymphoma | Latest news for Doctors, Nurses ... ... More
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor ... ScienceDirect.com - 20 May 2021 Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor ... ... More
FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Medpage Today - 01 Jun 2022 FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib ... More
FDA Places Partial Clinical Hold on Studies Featuring Umbralisib and Ublituximab in CLL and Non-Hodgkin Lymphoma Cancer Network - 01 Feb 2022 FDA Places Partial Clinical Hold on Studies Featuring Umbralisib and Ublituximab in CLL and Non-Hodgkin Lymphoma ... More
FDA Approves Umbralisib (Ukoniq) for Two Lymphomas Medscape - 08 Feb 2021 FDA Approves Umbralisib (Ukoniq) for Two Lymphomas ... More
FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns OncLive - 01 Jun 2022 FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns ... More
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib) BioSpace - 05 Feb 2021 TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib) ... More
Rhizen's cancer drug Umbralisib gets USFDA nod: Alembic Pharma The Economic Times - 09 Feb 2021 Rhizen's cancer drug Umbralisib gets USFDA nod: Alembic Pharma ... More
Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rival Fierce Pharma - 08 Feb 2021 Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rival ... More
Could hidden signals in public data have anticipated bad news for TG Therapeutics $TGTX? STAT - 13 Sep 2022 Could hidden signals in public data have anticipated bad news for TG Therapeutics $TGTX? ... More
First new chemical entity discovered by Indian scientists gets USFDA approval Business Today - 09 Feb 2021 First new chemical entity discovered by Indian scientists gets USFDA approval ... More
Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL Indications Cancer Network - 18 Apr 2022 Ublituximab/Umbralisib Applications Voluntary Withdrawn for CLL and SLL Indications ... More
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells ScienceDirect.com - 14 Jul 2020 The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells ... More
Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn OncLive - 15 Apr 2022 Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn ... More
FDA Concerned About Safety of Lymphoma Drug Medpage Today - 03 Feb 2022 FDA Concerned About Safety of Lymphoma Drug ... More
FDA Pulls Approval for TG Therapeutics' Cancer Drug BioSpace - 01 Jun 2022 FDA Pulls Approval for TG Therapeutics' Cancer Drug ... More
Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma OncLive - 18 Nov 2021 Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma ... More